Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.
Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar M, Türeli S, Wang W, Weiss CD, Smith DJ. Mühlemann B, et al. Among authors: screaton gr. bioRxiv [Preprint]. 2023 Sep 27:2023.09.27.559689. doi: 10.1101/2023.09.27.559689. bioRxiv. 2023. PMID: 37808679 Free PMC article. Preprint.
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies.
Davies AJ, Lleixà C, Siles AM, Gourlay DS, Berridge G, Dejnirattisai W, Ramírez-Santana C, Anaya JM, Falconar AK, Romero-Vivas CM, Osorio L, Parra B, Screaton GR, Mongkolsapaya J, Fischer R, Pardo CA, Halstead SK, Willison HJ, Querol L, Rinaldi S. Davies AJ, et al. Among authors: screaton gr. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200047. doi: 10.1212/NXI.0000000000200047. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36411078 Free PMC article.
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Dijokaite-Guraliuc A, Das R, Nutalai R, Zhou D, Mentzer AJ, Liu C, Supasa P, Dunachie SJ, Lambe T, Fry EE, Mongkolsapaya J, Ren J, Huo J, Stuart DI, Screaton GR. Dijokaite-Guraliuc A, et al. Among authors: screaton gr. Cell Discov. 2022 Nov 29;8(1):127. doi: 10.1038/s41421-022-00493-0. Cell Discov. 2022. PMID: 36443292 Free PMC article. No abstract available.
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.
Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, Duyvesteyn HME, Mentzer AJ, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Paterson NG, Williams MA, Hall DR, Plowright M, Newman TAH, Hornsby H, de Silva TI, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Pollard AJ, Lambe T, Goulder P; OPTIC consortium; ISARIC4C consortium; Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Huo J, et al. Among authors: screaton gr. Cell Rep. 2023 Jan 31;42(1):111903. doi: 10.1016/j.celrep.2022.111903. Epub 2022 Dec 14. Cell Rep. 2023. PMID: 36586406 Free PMC article.
Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny.
Hunt M, Hinrichs AS, Anderson D, Karim L, Dearlove BL, Knaggs J, Constantinides B, Fowler PW, Rodger G, Street T, Lumley S, Webster H, Sanderson T, Ruis C, Kotzen B, de Maio N, Amenga-Etego LN, Amuzu DSY, Avaro M, Awandare GA, Ayivor-Djanie R, Barkham T, Bashton M, Batty EM, Bediako Y, Belder D, Benedetti E, Bergthaler A, Boers SA, Campos J, Carr RAA, Chen YYC, Cuba F, Dattero ME, Dejnirattisai W, Dilthey A, Duedu KO, Endler L, Engelmann I, Francisco NM, Fuchs J, Gnimpieba EZ, Groc S, Gyamfi J, Heemskerk D, Houwaart T, Hsiao NY, Huska M, Hölzer M, Iranzadeh A, Jarva H, Jeewandara C, Jolly B, Joseph R, Kant R, Ki KKK, Kurkela S, Lappalainen M, Lataretu M, Lemieux J, Liu C, Malavige GN, Mashe T, Mongkolsapaya J, Montes B, Mora JAM, Morang'a CM, Mvula B, Nagarajan N, Nelson A, Ngoi JM, da Paixão JP, Panning M, Poklepovich T, Quashie PK, Ranasinghe D, Russo M, San JE, Sanderson ND, Scaria V, Screaton G, Sessions OM, Sironen T, Sisay A, Smith D, Smura T, Supasa P, Suphavilai C, Swann J, Tegally H, Tegomoh B, Vapalahti O, Walker A, Wilkinson RJ, Williamson C, Zair X; IMSSC2 Laboratory Network Consortium; de Oliveira T, Peto TE, Crook D, Corbett-Detig R, Iqbal Z. Hunt M, et al. bioRxiv [Preprint]. 2024 Nov 5:2024.04.29.591666. doi: 10.1101/2024.04.29.591666. bioRxiv. 2024. PMID: 38746185 Free PMC article. Preprint.
Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam.
Thanh TT, Tu NTK, Nguyet LA, Thuy CT, Thuan NLT, Ny NTH, Nhu LNT, Thanh LK, Hong NTT, Anh NT, Truong NT, Chau NVV, Yen LM, Van E P, Thuong NP, Van Truc N, Trung PH, Yap WC, Pandey R, Yee S, Weng R, Mongkolsapaya J, Dejnirattisai W, Hamers RL, Chantratita N, Screaton G, Dunachie SJ, Jones EY, Stuart DI, Dung NT, Thwaites G, Wang LF, Tan CW, Tan LV; SECOVARIANTS and ASSeSS Consortia. Thanh TT, et al. Int J Infect Dis. 2024 Oct;147:107173. doi: 10.1016/j.ijid.2024.107173. Epub 2024 Aug 2. Int J Infect Dis. 2024. PMID: 39094762 Free article.
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.
Asor R, Olerinyova A, Burnap SA, Kushwah MS, Soltermann F, Rudden LSP, Hensen M, Vasiljevic S, Brun J, Hill M, Chang L, Dejnirattisai W, Supasa P, Mongkolsapaya J, Zhou D, Stuart DI, Screaton GR, Degiacomi MT, Zitzmann N, Benesch JLP, Struwe WB, Kukura P. Asor R, et al. Among authors: screaton gr. Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2403260121. doi: 10.1073/pnas.2403260121. Epub 2024 Sep 19. Proc Natl Acad Sci U S A. 2024. PMID: 39298475 Free PMC article.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X, Munro AP, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dejnirattisai W, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Serafimova T, Saralaya D, Screaton GR, Sharma S, Sheridan R, Sturdy A, Supasa P, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. Liu X, et al. Among authors: screaton gr. J Infect. 2023 May;86(5):540-541. doi: 10.1016/j.jinf.2023.03.025. Epub 2023 Apr 12. J Infect. 2023. PMID: 37055303 Free PMC article. No abstract available.
136 results